AssetMark’s Tarsus Pharmaceuticals TARS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-14
Closed -$881 – 3901
2026
Q2
$881 Hold
14
– – ﹤0.01% 3173
2026
Q1
$982 Hold
14
– – ﹤0.01% 3038
2025
Q4
$1.15K Hold
14
– – ﹤0.01% 2902
2025
Q3
$832 Hold
14
– – ﹤0.01% 2824
2025
Q2
$567 Buy
+14
New +$630 ﹤0.01% 2722

Other funds holding TARS

AssetMark's TARS Position: Q3 2026 in Review

AssetMark sold out of Tarsus Pharmaceuticals (TARS) in Q3 2026, closing a stake of 14 shares — an estimated $881 sold.

AssetMark first reported a position in TARS in Q2 2025 and held it in 5 quarters. The position peaked at $1.15K in Q4 2025. 176 funds tracked by Wall St. Rank hold TARS as of Q3 2026.

  • AssetMark reported no remaining Tarsus Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • AssetMark sold 14 Tarsus Pharmaceuticals shares in Q3 2026, an estimated $881.
  • AssetMark first reported a position in Tarsus Pharmaceuticals in Q2 2025 and held it in 5 quarters.
  • AssetMark's Tarsus Pharmaceuticals position peaked at $1.15K in Q4 2025.
  • 176 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q3 2026.

Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.